Spots Global Cancer Trial Database for Lorlatinib Continuation Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Lorlatinib Continuation Study
Official Title: LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES
Study ID: NCT05144997
Interventions
Study Description
Brief Summary: The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UC Irvine Health, Orange, California, United States
The First affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
Beijing Cancer Hospital, Beijing, Beijing, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Hunan Cancer Hospital, Changsha, Hunan, China
General Hospital of Eastern Theater Command, Nanjing, Jiangsu, China
The first hospital of jilin university, Changchun City, Jilin, China
Jilin Cancer Hospital, Changchun, Jilin, China
Jilin Cancer Hospital, Changchun, Jilin, China
Sir Run Shaw Hospital, Hangzhou, Qiantang District, China
The Second Affiliated Hospital of PLA Air Force Medical University, Xi'an City, Shaanxi, China
Shanghai Chest Hospital, Shanghai, Shanghai, China
Sichuan Cancer Hospital, Chengdu, Sichuan, China
Sichuan Cancer Hospital, Chengdu, Sichuan, China
University Cancer Hospital, Beijing, , China
Beijing Chest Hospital, Capital Medical University, Beijing, , China
Fudan University Shanghai Cancer Center, Shanghai, , China
CHU de Rennes - Hôpital Pontchaillou, Rennes, , France
Institut Gustave Roussy, Villejuif Cedex, , France
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
National University Hospital, Singapore, , Singapore
National Cancer Centre Singapore, Singapore, , Singapore
National Cancer Centre Singapore, Singapore, , Singapore
Hospital Vall D´Hebron, Barcelona, Cataluña, Spain
Hospital Universitari Vall d'Hebron, Barcelona, , Spain
National Taiwan University Hospital, Taipei, , Taiwan
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
